Announcement by the Company's Board of Directors to convene the 2016 Annual General Shareholders' meeting
2017.Mar.09
OBI Pharma’s Board of Directors approves the announcement of the Company’s 2016 individual and consolidated financial statements
2017.Jan.26
Supplemental Information: OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)
2017.Jan.25
OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)
2017.Jan.23
OBI Pharma Inc. announces the change of Chief Operating Officer
2017.Jan.21
Clarification on the news article by Commercial Times
2017.Jan.11
Clarification on the news article by United Daily News E-Paper
2017.Jan.10
Clarification on the news article by Economic Daily News
2017.Jan.09
Press release by the Shihlin District Prosecutors Office, Taiwan
2016.Dec.30
Announcement of the signing of a Non-Binding Letter of Intent for OBI Pharma, Inc., to issue new shares to AbProtix, Inc., in exchange for up to 70% stake in AP Biosciences
